Overview

AVIDA The Vidaza® (Azacitidine) Patient Registry

Status:
Completed
Trial end date:
2010-08-31
Target enrollment:
Participant gender:
Summary
This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic syndromes (MDS) and other hematological disorders and the impact of these disorders on patients.
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Azacitidine